Novavax Downgraded by JPMorgan Chase. Time to Sell?

Novavax Downgraded by JPMorgan Chase. Time to Sell?

The Novavax (NASDAQ: NVAX) rollercoaster has been a wild one. The stock soared more than 2,700% in 2020 after the company received $1.6 billion from the U.S. government to develop the COVID-19 vaccine we now know as Nuvaxovid. Unfortunately, Novavax didn't receive authorization to sell its vaccine in the U.S. until this July.